SAM #HT9402-26-Q-9302

DoD Uniform Formulary Pharmaceutical Agents Solicitation

The Defense Health Agency (DHA), part of the Department of Defense, is soliciting quotations for newly approved pharmaceutical agents for potential inclusion in the DoD Uniform Formulary. - Government Buyer: - Defense Health Agency (DHA), Department of Defense - Contracting office located at JBSA Fort Sam Houston, Texas - OEMs and Vendors: - OEMs highlighted include manufacturers of Lifyorli, Quiofic, Widaplik, and Saphnelo - Products/Services Requested: - Pharmaceutical agents for formulary review: - Lifyorli (Oncological Agent, Glucocorticoid Receptor Antagonist) - Quiofic (Vitamin, Water Soluble) - Widaplik (Antihypertensive Agent) - Saphnelo (Immunosuppressive) - Specific product details, part numbers, and quantities are referenced in price list attachments - Unique/Notable Requirements: - Products must meet clinical and cost effectiveness standards - Compliance with DoD pharmacy regulations is required - Opportunity may result in Blanket Purchase Agreements (UF BPA) or Additional Discount Program Agreements (UF ADP) - Place of Performance: - JBSA Fort Sam Houston, Texas (contracting office) - San Antonio, Texas (place of performance)

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed:

a.  Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist

b. Quiofic - VITAMINS - WATER SOLUBLE

c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A

d. Saphnelo – IMMUNOSUPPRESSIVES – N/A  

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302.

Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. Additional Links:https://health.mil/PandT

View original listing